Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Ventyx Biosciences Inc.

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Ventyx Biosciences today and set a price target of $21.00. According to TipRanks, R...

Piper Sandler Sticks to Its Buy Rating for Ventyx Biosciences (VTYX)

Wells Fargo analyst Derek Archila maintained a Buy rating on Ventyx Biosciences today and set a price target of $14.00. According to TipRanks, Arch...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTYX	$8.19	-3.65%	783.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTYX	$8.19	-3.6%	783.04K
3
4
5
6

VTYX

VTYX

No Data Available

Get Ventyx Biosciences Inc. Data in Excel

Get Ventyx Biosciences Inc. Data in Excel